HeartBeam Inc. (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership and institutional investors. The funds will be used to accelerate the commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further develop its extended-wear patch and heart attack detection technologies, expand artificial intelligence capabilities, and for general corporate purposes.
The offering marks a significant milestone for HeartBeam as it seeks to transform cardiac care. The company’s platform technology is designed to be the first cable-free device capable of collecting ECG signals in three dimensions, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This innovation allows for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians can identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. The recent capital raise positions HeartBeam to expand its commercial footprint and invest in further research and development.
The news was initially reported by AINewsWire, a specialized communications platform focusing on advancements in artificial intelligence. For more details on the offering, the full press release is available at https://ibn.fm/9iNYY. Additional information about HeartBeam’s cleared indications for use can be found at https://www.heartbeam.com/indications.
HeartBeam is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The company’s platform is designed to redefine cardiac health management by enabling remote monitoring and diagnosis. With the new funding, HeartBeam aims to bring its innovative technology to more patients and healthcare providers, potentially reducing the need for in-clinic visits and improving outcomes for those with cardiac conditions.
